Liver cancer is the second leading cause of cancer related deaths worldwide. Due to this, there is a need for more predictive and relevant preclinical models to provide better insights into clinical outcomes when evaluating new cancer therapies. Patient derived xenograft (PDX) models display a true representation of the human genetic and phenotypic heterogeneity seen in patient populations and provide the most accurate approach to predicting an agent’s efficacy prior to entering the clinic. CrownBio’s collection consists of a large number of liver cancer PDX models, including several orthotopic models to more closely recapitulate the tumor microenvironment. Learn more about these models in the following publications: More
-Direct pharmacological inhibition of ??-catenin by RNA interference in tumors of diverse origin.pdf
-Molecular pathology of patient tumors, patient derived xenografts and cancer cell lines.pdf
-The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.pdf
Patient-derived xenografts (PDX) offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials.
CrownBio’s HuPrime® PDX collection well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.